

EGFR Gene, Targeted Mutation Analysis, 51
Mutation Panel, Tumor

Patient ID SA00150122	Patient Name TESTING, EGFRS NORMAL	Birth Date 1990-01-11	Gender M	Age 32
Order Number SA00150122	Client Order Number SA00150122	Ordering Physician CLIENT, CLIENT	Report Notes	
Account Information C7028846 DLMP Rochester		Collected 11 Jan 2022 08:00		

EGFR Gene, Mutation Analysis, Tumor

Result Summary

MCR

NO MUTATION IDENTIFIED

Result

MCR

Provided diagnosis: lung non-small cell carcinoma

EGFR status: Wild-type

This specimen is negative for all tested mutations (listed in Method).

Interpretation

1 MCR

Current data suggest that the efficacy of EGFR-targeted therapies in patients with non-small cell lung cancer is limited to tumors with mutations in the tyrosine kinase domain (exons 18–21) of EGFR. Thus, the absence of a detectable EGFR mutation within this tumor specimen suggests that these therapies may have limited therapeutic value for this patient. Consider additional testing (LNGPR / Lung Panel with Rearrangement Tumor) to rule out the presence of other mutations in EGFR or other genes that could impact therapeutic response.

ADDITIONAL INFORMATION

Microscopic examination was performed by a pathologist to identify areas of tumor for enrichment by macrodissection. A qualitative PCR-based assay employing fluorescently labeled probes was used to test for the presence of specific mutations within exons 18–21 of the EGFR gene (mutations at codon G719

in exon 18; small deletions in exon 19; T790M, S768I, and small insertions in exon 20; and L858R and L861Q in exon 21). Mutation nomenclature is based on GeneBank accession number NM_005228. Due to the sensitivity of the method being used, EGFR mutations cannot be reliably detected in samples containing less than 10% tumor cells. Samples are routinely macrodissected to enrich for tumor cells, with samples less than 10% rejected from further testing. Test results should be interpreted in the context of clinical findings, tumor sampling, and other laboratory data. If results obtained do not match other clinical or laboratory findings, please contact the laboratory for possible interpretation. Misinterpretation of results may occur if the information provided is inaccurate or incomplete.

Rare polymorphisms exist that could lead to false-negative or false-positive results.

Specimen

MCR

Tissue, Tumor

Tissue ID

MCR

1234

Released By

MCR

Ying-Chun Lo, M.D., Ph.D.

Received: 11 Jan 2022 09:24

Reported: 20 Jan 2022 11:19

Laboratory Notes

- 1 This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.

Performing Site Legend

Code	Laboratory	Address	Lab Director	CLIA Certificate
MCR	Mayo Clinic Laboratories - Rochester Main Campus	200 First Street SW, Rochester, MN 55905	William G. Morice M.D. Ph.D	24D0404292